Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles
- PMID: 29349898
- PMCID: PMC5894512
- DOI: 10.1002/cmdc.201700752
Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles
Abstract
Helenalin is a pseudoguaianolide natural product that targets Cys38 within the DNA binding domain of NF-κB transcription factor p65 (RelA). Helenalin contains two Michael acceptors that covalently modify cysteines: a α-methylene-γ-butyrolactone and a cyclopentenone. We recently reported two simplified helenalin analogues that mimic the biological activity of helenalin and contain both electrophilic moieties. To determine the individual contributions of the Michael acceptors toward NF-κB inhibition, we synthesized a small library of helenalin-based analogues containing various combinations of α-methylene-γ-butyrolactones and cyclopentenones. The kinetics of thiol addition to a subset of the analogues was measured to determine the relative thiol reactivities of the embedded electrophiles. Additionally, the cellular NF-κB inhibitory activities of the analogues were determined to elucidate the contributions of each Michael acceptor to biological potency. Our studies suggest the α-methylene-γ-butyrolactone contributes most significantly to the NF-κB inhibition of our simplified helenalin analogues.
Keywords: Michael acceptors; bis-electrophiles; cysteine reactive; helenalin; p65/RelA transcription factor.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figures




Similar articles
-
Targeting NF-κB p65 with a Helenalin Inspired Bis-electrophile.ACS Chem Biol. 2017 Jan 20;12(1):102-113. doi: 10.1021/acschembio.6b00751. Epub 2016 Nov 28. ACS Chem Biol. 2017. PMID: 28103680 Free PMC article.
-
Surface plasmon resonance analysis of nuclear factor-kappaB protein interactions with the sesquiterpene lactone helenalin.Anal Biochem. 2010 Jun 1;401(1):30-7. doi: 10.1016/j.ab.2010.02.020. Epub 2010 Feb 20. Anal Biochem. 2010. PMID: 20175984
-
The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65.J Biol Chem. 1998 Dec 11;273(50):33508-16. doi: 10.1074/jbc.273.50.33508. J Biol Chem. 1998. PMID: 9837931
-
Cysteine Alkylation in Enzymes and Transcription Factors: A Therapeutic Strategy for Cancer.Cancers (Basel). 2025 Jun 3;17(11):1876. doi: 10.3390/cancers17111876. Cancers (Basel). 2025. PMID: 40507356 Free PMC article. Review.
-
The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.Front Pharmacol. 2020 Sep 3;11:1297. doi: 10.3389/fphar.2020.01297. eCollection 2020. Front Pharmacol. 2020. PMID: 33013366 Free PMC article. Review.
Cited by
-
Electrophilic reactivities of cyclic enones and α,β-unsaturated lactones.Chem Sci. 2021 Feb 9;12(13):4850-4865. doi: 10.1039/d0sc06628a. Chem Sci. 2021. PMID: 34163736 Free PMC article.
-
Localization of Sesquiterpene Lactones Biosynthesis in Flowers of Arnica Taxa.Molecules. 2023 May 27;28(11):4379. doi: 10.3390/molecules28114379. Molecules. 2023. PMID: 37298857 Free PMC article.
-
Stapling proteins in the RELA complex inhibits TNFα-induced nuclear translocation of RELA.RSC Chem Biol. 2021 Oct 28;3(1):32-36. doi: 10.1039/d1cb00183c. eCollection 2022 Jan 5. RSC Chem Biol. 2021. PMID: 35128406 Free PMC article.
-
Network Pharmacology and Experimental Validation of the Therapeutic Effect of Baji Capsule on LPS-Induced Osteoporosis.Orthop Res Rev. 2025 Feb 11;17:61-81. doi: 10.2147/ORR.S488478. eCollection 2025. Orthop Res Rev. 2025. PMID: 39958436 Free PMC article.
-
Dimers of isatin derived α-methylene-γ-butyrolactone as potent anti-cancer agents.Bioorg Med Chem Lett. 2022 Jun 1;65:128713. doi: 10.1016/j.bmcl.2022.128713. Epub 2022 Apr 1. Bioorg Med Chem Lett. 2022. PMID: 35367592 Free PMC article.
References
-
- Xiao G, Fu J. Am. J. Cancer Res. 2011;1:192–221. - PMC - PubMed
- Aggarwal BB. Cancer Cell. 2004;6:203–208. - PubMed
- Herrington FD, Carmody RJ, Goodyear CS. J. Biomol. Screen. 2016;21:223–242. - PubMed
- Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M, Evans PC. Clin. Sci. 2010;118:593–605. - PubMed
- Basseres DS, Baldwin AS. Oncogene. 2006;25:6817–6830. - PubMed
- Hayden MS, Ghosh S. Cell. 2008;132:344–362. - PubMed
- Huxford T, Ghosh G. Cold Spring Harbor Perspect. Biol. 2009;1:a000075. - PMC - PubMed
-
- Gilmore TD, Herscovitch M. Oncogene. 2006;25:6887–6899. - PubMed
-
- Lagoutte R, Patouret R, Winssinger N. Curr. Opin. Chem. Biol. 2017;39:54–63. - PubMed
- Huhn AJ, Guerra RM, Harvey EP, Bird GH, Walensky LD. Cell Chem. Biol. 2016;23:1123–1134. - PMC - PubMed
- Lagoutte R, Serba C, Abegg D, Hoch DG, Adibekian A, Winssinger N. Nat. Comm. 2016;7:12470. - PMC - PubMed
- Potashman MH, Duggan ME. J. Med. Chem. 2009;52:1231–1246. - PubMed
- Singh J, Petter RC, Baillie TA, Whitty A. Nat. Rev. Drug Discov. 2011;10:307–317. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous